Last reviewed · How we verify
Fluzone High-Dose vaccine, 2018-2019 formulation — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
Fluzone High-Dose vaccine, 2018-2019 formulation (Fluzone High-Dose vaccine, 2018-2019 formulation) — Sanofi Pasteur, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fluzone High-Dose vaccine, 2018-2019 formulation TARGET | Fluzone High-Dose vaccine, 2018-2019 formulation | Sanofi Pasteur, a Sanofi Company | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fluzone High-Dose vaccine, 2018-2019 formulation CI watch — RSS
- Fluzone High-Dose vaccine, 2018-2019 formulation CI watch — Atom
- Fluzone High-Dose vaccine, 2018-2019 formulation CI watch — JSON
- Fluzone High-Dose vaccine, 2018-2019 formulation alone — RSS
Cite this brief
Drug Landscape (2026). Fluzone High-Dose vaccine, 2018-2019 formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/fluzone-high-dose-vaccine-2018-2019-formulation. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab